Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck

NEW YORK, August 20, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.

--
Johnson & Johnson Research Reports
On August 8, 2014, Janssen Pharmaceuticals, Inc. (Janssen), a subsidiary of Johnson & Johnson announced that it has received approval from the U.S. Food and Drug Administration (FDA) for INVOKAMET™, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes. INVOKAMET™ provides the clinical attributes of INVOKANA® (canagliflozin), the first sodium glucose co-transporter 2 (SGLT2) inhibitor available in the U.S., together with metformin, which is commonly prescribed early in the treatment of type 2 diabetes. INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the U.S. Jimmy Ren, Ph.D., Therapeutic Area Lead, Metabolics, Medical Affairs, Janssen, said, "As with INVOKANA®, INVOKAMET™ provides adults with type 2 diabetes an oral therapy that lowers blood sugar and is also associated with reductions in body weight and systolic blood pressure." The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/JNJ/report.pdf

--
Biogen Idec Inc. Research Reports
On August 15, 2014, Biogen Idec Inc. (Biogen) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). The Company stated that PLEGRIDY is the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe. Further, the approval of PLEGRIDYTM is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients. George A. Scangos, Ph.D., CEO, Biogen, said, "PLEGRIDY offers people with MS robust efficacy, a safety profile consistent with the established interferon class, and significantly fewer injections than other beta interferon treatments." The full research reports on Biogen are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/BIIB/report.pdf

--
Amgen, Inc. Research Reports
On August 13, 2014, Amgen, Inc. and its subsidiary Onyx Pharmaceuticals, Inc. (Onyx), jointly announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95% CI, 0.760, 1.249). The Companies informed that the 315-patient, open-label study evaluated single-agent Kyprolis® (carfilzomib) for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma. Nearly all patients in the control arm received cyclophosphamide, and patients were heavily pretreated and had received a median of five therapeutic regimens prior to study entry. Pablo J. Cagnoni, M.D., President, Onyx, said, "While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results from the recent positive ASPIRE Phase 3 clinical trial will be sufficient to support regulatory submissions around the world." The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/AMGN/report.pdf

--
Medtronic, Inc. Research Reports
On August 11, 2014, Medtronic, Inc. (Medtronic) reported that it will honor twenty-five long-distance runners who benefit from medical technology, with the title of "Medtronic Global Heroes" during the Medtronic Twin Cities Marathon or TC 10 Mile on October 5, 2014. The Company informed that this year's team includes runners from 10 different countries: Australia, Brazil, Canada, China, Colombia, Israel, Italy, Switzerland, U.K. and the U.S. Further, each runner has a medical device to treat conditions such as heart disease, diabetes, spinal disorders, chronic pain or neurological disorders. In addition, each winner is selected by Twin Cities In Motion, the non-profit organization that directs the Medtronic Twin Cities Marathon. The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/MDT/report.pdf

--
Merck Research Reports
On August 13, 2014, Merck & Co., Inc. (Merck) announced that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. The Company informed that BELSOMRA is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. According to Merck, the mechanism by which BELSOMRA exerts its therapeutic effect is presumed to be through antagonism of orexin receptors. In the clinical trials to support efficacy, BELSOMRA was superior to placebo for sleep latency and sleep maintenance as assessed both objectively by polysomnography and subjectively by patient-estimated sleep latency. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/MRK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED